| Similar Articles |
|---|
 |
The Motley Fool
January 12, 2007
Brian Lawler |
What's Next for Northfield Labs? When Northfield released results from its phase 3 trial for PolyHeme, its shares fell almost 60% in one day. But Northfield again said it's not giving up on PolyHeme and would eventually apply to the FDA to market the drug.   |
The Motley Fool
October 11, 2006
Brian Lawler |
Waiting on Northfield The development-stage drug company waits for clinical trial results. Until the fate of its lead product is known, most of Northfield's financial results will be of peripheral importance to investors at best. |
The Motley Fool
May 24, 2007
Brian Lawler |
Learn From Northfield's Bloody Results Northfield announces clinical trial results that investors can learn from. As long as they at least give the appearance of trying to advance their compounds forward, development-stage drugmakers can go on for years always getting investor funding from somewhere. |
The Motley Fool
July 10, 2006
Brian Lawler |
Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced. |
The Motley Fool
September 26, 2007
Brian Lawler |
Following the Fallen Biotech Class of 2006 Let's take a look a list of the biggest development stage drugmaker disasters from 2006 and how the tiny drug developers have fared since they announced their clinical trial or regulatory failures. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
December 20, 2006
Billy Fisher |
Northfield Shares Head South Anemic results for a blood substitute leave shares run down. |
The Motley Fool
January 10, 2007 |
The Trials of Northfield Labs: Fool by Numbers The pharmaceutical released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
Chemistry World
May 14, 2009
Rebecca Trager |
Bloodshed for blood substitute makers The synthetic blood business has taken a hit as regulators pan products and two major players are brought to the brink of collapse. |
Chemistry World
May 1, 2008
Rebecca Trager |
Blood Substitutes Pose Worrying Risks Oxygen-carrying blood substitutes currently in clinical trials are associated with a much higher likelihood of serious adverse events such as heart attack and death. |
